|
|
Blood, 1 September 2004, Vol. 104, No. 5, pp. 1450-1458.
Prepublished online as a Blood First Edition Paper on May 18, 2004; DOI 10.1182/blood-2004-03-0868.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
Jun Yuan,
David B. Lovejoy, and
Des R. Richardson
From the Iron Metabolism and Chelation Program, Children's Cancer Institute Australia for Medical Research, Randwick, Sydney, Australia.
Aroylhydrazone and thiosemicarbazone iron (Fe) chelators have potent antitumor activity. The aim of the current study was to examine the antitumor effects and mechanisms of action of a novel series of Fe chelators, the di-2-pyridyl thiosemicarbazones. Of 7 new chelators synthesized, 4 showed pronounced antiproliferative effects. The most active chelator was Dp44mT, which had marked and selective antitumor activity—for example, an IC50 of 0.03 µM in neuroepithelioma cells compared with more than 25 µM in mortal fibroblasts. Indeed, this antiproliferative activity was the greatest yet observed for an Fe chelator. Efficacy was greater than it was for the cytotoxic ligand 311 and comparable to that of the antitumor agent doxorubicin. Strikingly, Dp44mT significantly (P < .01) decreased tumor weight in mice to 47% of the weight in the control after only 5 days, whereas there was no marked change in animal weight or hematologic indices. Terminal deoxyribonucleotidyl transferase (TdT)–mediated dUTP nick end-labeling (TUNEL) staining demonstrated apoptosis in tumors taken from mice treated with Dp44mT. This chelator caused a marked increase of caspase-3 activity in murine Madison-109 (M109) cells. Caspase activation was at least partially mediated by the release of mitochondrial holo-cytochrome c (h-cytc) after incubation with Dp44mT. In conclusion, Dp44mT is a novel, highly effective antitumor agent in vitro and in vivo that induces apoptosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Fu and D. R. Richardson
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
Blood,
July 15, 2007;
110(2):
752 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl
Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
J. Pharmacol. Exp. Ther.,
December 1, 2006;
319(3):
1336 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Kovacevic and D. R. Richardson
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
Carcinogenesis,
December 1, 2006;
27(12):
2355 - 2366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond
Clin. Cancer Res.,
December 1, 2006;
12(23):
6876 - 6883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Whitnall, J. Howard, P. Ponka, and D. R. Richardson
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
PNAS,
October 3, 2006;
103(40):
14901 - 14906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Richardson and D. B. Lovejoy
"Iron mining" to inhibit tumor growth
Blood,
October 1, 2006;
108(7):
2140 - 2140.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nie, G. Chen, A. D. Sheftel, K. Pantopoulos, and P. Ponka
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin
Blood,
October 1, 2006;
108(7):
2428 - 2434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Cole, A. M. Donoghue, I. Reyes-Herrera, N. Rath, and D. J. Donoghue
Efficacy of Iron Chelators on Campylobacter Concentrations in Turkey Semen
Poult. Sci.,
August 1, 2006;
85(8):
1462 - 1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Kalinowski and D. R. Richardson
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Pharmacol. Rev.,
December 1, 2005;
57(4):
547 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Sterba, T Simunek, Y Mazurova, M Adamcova, O Popelova, J Kaplanova, P Ponka, and V Gersl
Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits
Human and Experimental Toxicology,
November 1, 2005;
24(11):
581 - 589.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Turner, C. Koumenis, T. E. Kute, R. P. Planalp, M. W. Brechbiel, D. Beardsley, B. Cody, K. D. Brown, F. M. Torti, and S. V. Torti
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation
Blood,
November 1, 2005;
106(9):
3191 - 3199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Block
Integrative Physician's Perspective, With a Special Consideration of St John's Wort
Integr Cancer Ther,
September 1, 2005;
4(3):
261 - 265.
[PDF]
|
|
|
|
|
|
|
T. B. Chaston, R. N. Watts, J. Yuan, and D. R. Richardson
Potent Antitumor Activity of Novel Iron Chelators Derived from Di-2-Pyridylketone Isonicotinoyl Hydrazone Involves Fenton-Derived Free Radical Generation
Clin. Cancer Res.,
November 1, 2004;
10(21):
7365 - 7374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. T.V. Le and D. R. Richardson
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation
Blood,
November 1, 2004;
104(9):
2967 - 2975.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
